Search

Arnold J Mcauley

from Moorpark, CA
Age ~65
Get Report
Also known as:
Arnold Alison Mcauley, Arnold Alison Mc Auley, Arnold Mc Auley, Arnold Mcaule, Arnold Meauley, Julian Mcauley Arnold, Julien Mcauley Arnold
Related to:
Alison Mcauley, 65Alison H Mcauley, 58Catherine Mcauley, 29
Connected to:
Alexander M Mcauley, 40Aron P Mcauley, 56Brenda J Mcauley, 53Chloe L Mcauley, 56Christina A Mcauley, 32Ciaran Mcauley, 46Crystal A Mcauley, 52Dee Mcauley, 54Elaine M Mcauley, 93Fred R Mcauley, 50

Arnold Mcauley Phones & Addresses

  • Moorpark, CA
  • Newbury Park, CA
  • Duarte, CA
  • Diamond Bar, CA
  • Ventura, CA

Resumes

Resumes

Arnold Mcauley Photo 1

Principal Scientist

View page
Location:
6931 Lafayette St, Moorpark, CA 93021
Industry:
Biotechnology
Work:
Amgen
Principal Scientist
Amgen Prepivotal Drug Product Technologies
Scientist
Baxter International Inc. 1991 - 1994
Scientist Iii
Bio Products Laboratory Limited Sep 1987 - Mar 1991
Senior Research Assistant
Education:
University of Essex 1984 - 1986
Master of Science, Masters, Chemistry University of Essex 1981 - 1984
Bachelors, Bachelor of Science, Chemistry
Skills:
Biopharmaceuticals
Monoclonal Antibodies
Biotechnology
Protein Chemistry
Chromatography
Technology Transfer
Protein Purification
Life Sciences
Antibodies
Purification
Assay Development
Hplc
Drug Discovery
Drug Development
Elisa
Formulation
Glp
Lc Ms
Mass Spectrometry
Sds Page
Ind
Pharmaceutical Industry
Lifesciences
High Performance Liquid Chromatography
Lyophilization
Protein Formulation Development
Languages:
English
Arnold Mcauley Photo 2

Arnold Mcauley

View page

Publications

Us Patents

Stable Polypeptide Formulations

View page
US Patent:
8241632, Aug 14, 2012
Filed:
Mar 5, 2010
Appl. No.:
12/718898
Inventors:
Douglas Rehder - Seattle WA, US
Pavel Bondarenko - Thousand Oaks CA, US
Dirk Chelius - Geretsried, DE
Arnold McAuley - Moorpark CA, US
Masazumi Matsumura - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/395
C07K 16/00
C12P 21/08
US Classification:
4241581, 53038824
Abstract:
The invention provides a formulation including a buffer having a pH less than 6. 0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6. 0 and an excipient comprising a sugar or polyol.

Stable Formulations

View page
US Patent:
20080112953, May 15, 2008
Filed:
Oct 5, 2007
Appl. No.:
11/973200
Inventors:
Arnold McAuley - Moorpark CA, US
Douglas Rehder - Seattle WA, US
Masazumi Matsumura - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/395
US Classification:
424133100, 424145100
Abstract:
The invention provides a formulation including an acetic acid buffer, a glutamic acid buffer or a succinic acid buffer with a pH from about 4.5-7.0, at least one excipient comprising a sugar or a polyol and an effective amount of a therapeutic antibody. The buffer can include a salt of acetate, glutamate or succinate and the sugar or polyol can include glycerol, sucrose, trehalose or sorbitol. The therapeutic antibody can include a human antibody, a humanized antibody, a chimeric antibody, or a functional fragment thereof.

Stable Polypeptide Formulations

View page
US Patent:
20080124326, May 29, 2008
Filed:
Oct 5, 2007
Appl. No.:
11/973051
Inventors:
Douglas Rehder - Seattle WA, US
Pavel Bondarenko - Thousand Oaks CA, US
Dirk Chelius - Geretsried, DE
Arnold McAuley - Moorpark CA, US
Masazumi Matsumura - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/395
C07K 16/28
US Classification:
4241331, 4241581, 4241431, 5303892
Abstract:
The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol.

Systems And Approaches For Drug Delivery

View page
US Patent:
20220362104, Nov 17, 2022
Filed:
Oct 23, 2020
Appl. No.:
17/770355
Inventors:
- Thousand Oaks CA, US
- Munich, DE
Wei Qi - Thousands Oaks CA, US
Arnold J. McAuley - Thousand Oaks CA, US
MIchael Schneider - Thousand Oaks CA, US
Chia-Jung Wu - Redondo Beach CA, US
Twinkle R. Christian - Thousand Oaks CA, US
Heather N. Franey - Ventura CA, US
Bharadwaj Jagannathan - Thousand Oaks CA, US
Jeffrey Abel - Thousand Oaks CA, US
Franz Dietzel - Munich, DE
International Classification:
A61J 1/14
A61M 5/14
G01N 33/15
Abstract:
An approach for determining material compatibility for components of a drug delivery system is provided that includes using surface zeta-potential analytical method to evaluate surface interactions between a desired molecule and at least one material present within a given IV-bag system.

Pharmaceutical Composition Comprising Bispecific Antibody Constructs For Improved Storage And Administration

View page
US Patent:
20190151448, May 23, 2019
Filed:
May 7, 2018
Appl. No.:
15/972489
Inventors:
- Thousand Oaks CA, US
Lingwen Cui - Thousand Oaks CA, US
Devrishi Goswami - Thousand Oaks CA, US
Joon Huh - Culver City CA, US
Bharadwaj Jagannathan - Thousand Oaks CA, US
Sekhar Kanapuram - Thousand Oaks CA, US
Arnold McAuley - Moorpark CA, US
Michael Schneider - Thousand Oaks CA, US
Ananthakrishnan G. Sethuraman - Newbury Park CA, US
Michael Treuheit - Newbury Park CA, US
Jun Zhang - Newbury Park CA, US
International Classification:
A61K 39/395
C07K 16/28
A61K 47/10
A61K 47/14
A61K 47/24
A61K 47/12
A61K 47/26
A61K 47/18
C07K 16/46
Abstract:
The present invention provides an improved pharmaceutical composition for storage and administration comprising (a) a bispecific antibody construct comprising a first domain binding to a target cell surface antigen and a second domain binding to a second antigen, wherein the bispecific antibody construct is present at a concentration in the range from about 0.5 μg/ml to 20 mg/ml, (b) a preservative at a concentration effective to inhibit the growth of microbes, and (c) a diluent wherein bispecific antibody construct is stable and recoverable.

Protein Formulations

View page
US Patent:
20170209582, Jul 27, 2017
Filed:
Jun 15, 2015
Appl. No.:
15/321671
Inventors:
- Thousand Oaks CA, US
Arnold J. MCAULEY - Moorpark CA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
A61K 47/22
A61K 47/26
A61K 39/395
A61K 9/19
A61K 9/00
A61K 38/18
C07K 16/22
Abstract:
The present disclosure provides solid protein formulations that are stable over a variety of temperatures for extended time periods. The present disclosure also provides methods of making and using these formulations.
Control profile
Arnold J Mcauley from Moorpark, CA, age ~65 Get Report